DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit
Rhea-AI Summary
DBV Technologies (Nasdaq: DBVT) announced that CEO Daniel Tassé will participate in a fireside chat at the Guggenheim Securities Emerging Outlook: Biotech Summit in New York on February 12, 2026 at 2:30pm ET. A live webcast will be available and a replay will remain on the company site for 90 days.
Investors can access the live webcast via the company’s Events page and view the replay through the investor website.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
DBVT was down 0.93% while peers showed mixed moves (e.g., CADL -1.03%, ANNX -1.4%, CAPR +1.92%, NGNE +1.97%). With no peers in the momentum scanner and no same-day peer news, this conference participation headline appears stock-specific rather than part of a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 05 | Voting rights update | Neutral | -8.3% | Updated disclosure of total shares and voting rights as of Jan 31, 2026. |
| Jan 16 | Warrant exercise proceeds | Positive | +0.5% | Reported €166.7M gross proceeds from full exercise of March 2025 warrants. |
| Jan 12 | Voting rights revision | Neutral | -5.0% | Revised total shares and voting rights as of Dec 31, 2025 after warrant exercises. |
| Jan 07 | Liquidity contract report | Neutral | +8.2% | Half-year liquidity contract report detailing share and cash balances and trades. |
| Jan 05 | Voting rights update | Neutral | -10.8% | Initial Dec 31, 2025 share and voting-rights disclosure under AMF regulations. |
Recent administrative and capital-structure disclosures often coincided with sharp price swings, especially negative reactions to voting-rights/share-count updates, while financing and liquidity-related news saw more mixed responses.
Over the last months, DBV issued several capital-structure and administrative updates. Voting-rights/share-count disclosures on Dec 31, 2025 and Jan 31, 2026 tied to news IDs 952991, 956200, and 1009439 were followed by declines of -10.81%, -5.02%, and -8.33%. In contrast, the half-year liquidity contract report (954382) saw a +8.18% move, and the March 2025 warrant-exercise proceeds update (1000390) had a modest +0.53% reaction. Today’s conference-participation news is more routine than these prior share and liquidity events.
Market Pulse Summary
This announcement highlights DBV’s participation in a Guggenheim biotech summit, with the CEO presenting on February 12 at 2:30pm ET and a webcast replay available for 90 days. It underscores ongoing investor-relations engagement rather than a new clinical or financial milestone. In context of recent sizeable moves following voting-rights and warrant-related news, investors may later focus on any disclosed pipeline, regulatory, or commercialization details that emerge from the discussion.
AI-generated analysis. Not financial advice.
Châtillon, France, February 9, 2025
DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today announced Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the Guggenheim Securities Emerging Outlook: Biotech Summit which is being held February 11-12, 2026 in New York, NY. Mr. Tassé’s presentation is scheduled for Thursday, February 12, at 2:30pm ET.
A live webcast of the fireside chat can be accessed here and will also be available on the Events section of the Company’s Investors website: https://dbv-technologies.com/investor-overview/events/
A replay will be available on DBV Technologies’ website for 90 days after the event.
About DBV Technologies
DBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of VIASKIN® Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).
DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309). For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.
VIASKIN is a registered trademark of DBV Technologies.
Investor Contact
Jonathan Neely
DBV Technologies
jonathan.neely@dbv-technologies.com
Media Contact
Brett Whelan
DBV Technologies
brett.whelan@dbv-technologies.com
Attachment
FAQ
When will DBV Technologies (DBVT) present at the Guggenheim Biotech Summit in 2026?
How can investors watch the DBV Technologies (DBVT) fireside chat on February 12, 2026?
Will the DBV Technologies (DBVT) presentation at the Guggenheim summit be available after the event?
Who from DBV Technologies (DBVT) will participate in the Guggenheim Emerging Outlook: Biotech Summit?
Where can I find the webcast link for the DBV Technologies (DBVT) Guggenheim summit presentation?
